Literature DB >> 19002108

Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts.

Laura Sanz1, Angel M Cuesta, Clara Salas, César Corbacho, Carmen Bellas, Luís Alvarez-Vallina.   

Abstract

In vivo models of human tumor vasculature are essential for the study of tumor angiogenesis and validation of therapeutic targets. To date, however, few standardized animal models of human tumor angiogenesis have been characterized. It was recently shown that human renal cell and prostate carcinoma primary xenografts, established from biopsy specimens, contained vessels lined mainly by human endothelial cells 1 month after implantation in immunodeficient mice. We selected colorectal cancer (CRC) as a primary xenograft model and studied the response of the vascular compartment to the new microenvironment during the same lapse of time. Immunohistochemical analysis of the origin of endothelial cells demonstrated that, in contrast to the mentioned study, human endothelial cells were rapidly substituted by their murine counterparts (nearly 50% by day 10 after implantation). Apoptotic human endothelial cells could not be detected 10 days after implantation, suggesting that apoptosis is not the mechanism underlying their replacement. Interestingly, host endothelial cells were found to colocalize with human laminin, suggesting a colonization of human vascular basement membranes after human endothelial cell disappearance. To rule out that the differences observed between the fate of human vasculature in the CRC model and those previously reported were because of methodological aspects, we established renal cell carcinoma (RCC) primary xenografts using the same protocol. In clear contrast with CRC xenografts, vasculature within RCC xenografts was mostly of human origin 35 days after implantation. These results support the notion of angiogenic heterogeneity in malignant neoplasms. Elucidation of the molecular mechanisms that determine persistence or disappearance of human endothelial cells in different tumor contexts can help to shed light on the intimate regulation of the angiogenic process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002108     DOI: 10.1038/labinvest.2008.108

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

1.  HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Authors:  Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

Review 2.  Selection strategies for anticancer antibody discovery: searching off the beaten path.

Authors:  David Sánchez-Martín; Morten Dræby Sørensen; Simon Lykkemark; Laura Sanz; Peter Kristensen; Erkki Ruoslahti; Luis Álvarez-Vallina
Journal:  Trends Biotechnol       Date:  2015-03-26       Impact factor: 19.536

3.  Patient-derived Xenografts from Colorectal Carcinoma: A Temporal and Hierarchical Study of Murine Stromal Cell Replacement.

Authors:  Celia Chao; Steve G Widen; Thomas G Wood; John R Zatarain; Paul Johnson; Aakash Gajjar; Guillermo Gomez; Suimin Qiu; Jill Thompson; Heidi Spratt; Mark R Hellmich
Journal:  Anticancer Res       Date:  2017-07       Impact factor: 2.480

Review 4.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

Review 5.  One mouse, one patient paradigm: New avatars of personalized cancer therapy.

Authors:  Prerna Malaney; Santo V Nicosia; Vrushank Davé
Journal:  Cancer Lett       Date:  2013-10-22       Impact factor: 8.679

6.  Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.

Authors:  Hua Li; Sarah Wheeler; Yongseok Park; Zhenlin Ju; Sufi M Thomas; Michele Fichera; Ann M Egloff; Vivian W Lui; Umamaheswar Duvvuri; Julie E Bauman; Gordon B Mills; Jennifer R Grandis
Journal:  Mol Cancer Res       Date:  2015-12-18       Impact factor: 5.852

Review 7.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

8.  Human proangiogenic circulating hematopoietic stem and progenitor cells promote tumor growth in an orthotopic melanoma xenograft model.

Authors:  Julie A Mund; Harlan Shannon; Anthony L Sinn; Shanbao Cai; Haiyan Wang; Kamnesh R Pradhan; Karen E Pollok; Jamie Case
Journal:  Angiogenesis       Date:  2013-07-23       Impact factor: 9.596

9.  Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases.

Authors:  Arnaud Blomme; Gaetan Van Simaeys; Gilles Doumont; Brunella Costanza; Justine Bellier; Yukihiro Otaka; Félicie Sherer; Pierre Lovinfosse; Sébastien Boutry; Ana Perez Palacios; Edwin De Pauw; Touko Hirano; Takehiko Yokobori; Roland Hustinx; Akeila Bellahcène; Philippe Delvenne; Olivier Detry; Serge Goldman; Masahiko Nishiyama; Vincent Castronovo; Andrei Turtoi
Journal:  Oncogene       Date:  2017-12-15       Impact factor: 9.867

10.  A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells.

Authors:  Daniela Burgos-Ojeda; Karen McLean; Shoumei Bai; Heather Pulaski; Yusong Gong; Ines Silva; Karl Skorecki; Maty Tzukerman; Ronald J Buckanovich
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.